Drp1 inhibition was also effective in relieving myocardial dysfunction in in vitro and in vivo models of insulin resistance and metabolic cardiomyopathy, as well as cardiac hypertrophy and HF [56, 100]. The gene discussed is DNM1L; the disease is cardiac hypertrophy.